Betahistine Non-pulsatile Prolonged-Release Matrix
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current prolonged-release compositions of betahistine dihydrochloride for treating Ménière's disease suffer from premature release, leading to fluctuations in plasma concentrations and adverse effects due to its high solubility and hygroscopicity, making it difficult to maintain therapeutic levels for 24 hours with once-daily administration.
Innovation Solution
A non-pulsatile 24-hour prolonged-release oral solid composition of betahistine dihydrochloride, formulated with a specific dissolution profile and hydrophilic matrix forming agents, which ensures stable release and bioequivalence to twice-daily immediate release formulations, reducing plasma concentration fluctuations and improving patient compliance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If matrix-based prolonged-release compositions are used to extend drug release duration, then the duration of action is improved, but premature release and dose-dumping effect occur causing plasma concentration fluctuations
Solution Approach 1:
The patent uses a composite matrix system combining hydrophilic polymers (HPMC, carbopol) with hydrophobic materials (beeswax, microcrystalline cellulose) to create a dual-mechanism release system. The hydrophilic components form gel barriers that control water penetration, while hydrophobic components provide structural integrity and prevent premature drug release, resolving the contradiction between extended duration and concentration stability.
Solution Approach 2:
The patent systematically varies critical formulation parameters including polymer types (HPMC viscosity grades), polymer ratios, wax content (0-20%), and particle size distributions to optimize the release profile. By adjusting these parameters, the formulation achieves sustained release over 12-24 hours while maintaining plasma concentration stability and eliminating dose-dumping effects.
2Ease of operation
If betahistine dihydrochloride is formulated for once-daily administration, then patient compliance is improved, but maintaining therapeutic plasma levels for 24 hours is difficult due to high solubility and hygroscopicity
Solution Approach 1:
The patent introduces hydrophilic matrix-forming agents (HPMC, carbopol) as intermediary substances that mediate between the highly soluble betahistine dihydrochloride and the gastrointestinal environment. These polymers form gel barriers that control drug release kinetics, enabling once-daily administration while maintaining therapeutic plasma levels throughout the 24-hour period.
Solution Approach 2:
The patent utilizes porous matrix structures formed by hydrophilic polymers that create controlled pore networks for drug diffusion. The porous gel matrix allows sustained drug release by controlling water penetration and drug dissolution rates, enabling 24-hour therapeutic coverage from a single daily dose despite the high solubility of betahistine dihydrochloride.
3Duration of action of moving object
If high doses of betahistine dihydrochloride are administered to achieve prolonged therapeutic effect, then duration of action is improved, but adverse effects increase due to plasma concentration fluctuations
Solution Approach 1:
The patent creates a dynamic release system where the gel matrix structure evolves over time, transitioning from an initial gel formation phase to a sustained diffusion phase. This dynamic behavior allows the formulation to adapt release rates to maintain consistent plasma concentrations, providing prolonged therapeutic effects at lower doses while minimizing adverse effects associated with concentration fluctuations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition maintains therapeutic plasma levels of betahistine and its metabolite for 24 hours with reduced fluctuations, achieving bioequivalence to twice-daily administration, enhancing patient adherence and treatment effectiveness while maintaining stability despite high water solubility and hygroscopicity.
Implementation Method 1
the composition exhibits a dissolution profile according to which: up to 30% by weight of betahistine is dissolved in 1 hour; from 35% to 45% by weight of betahistine is dissolved in 2 hours
Implementation Method 2
from 61% to 80% by weight of betahistine is dissolved in 8 hours; from 81% to 97% by weight of betahistine is dissolved in 16 hours; and from 98% to 100% by weight of betahistine is dissolved in 24 hours
Implementation Method 3
formulated with a specific dissolution profile and hydrophilic matrix forming agents, which ensures stable release
Data Source
AI summary
An oral solid non-pulsatile 24 hours prolonged-release composition including an amount of betahistine, or of a pharmaceutically acceptable salt thereof, equivalent to 48 mg of betahistine dihydrochloride, together with one or more pharmaceutically acceptable excipients or carriers, wherein the composition exhibits a dissolution profile according to which: up to 30% by weight of betahistine is dissolved in 1 hour; from 35% to 45% by weight of betahistine is dissolved in 2 hours; from 46% to 60% by weight of betahistine is dissolved in 4 hours; from 61% to 80% by weight of betahistine is dissolved in 8 hours; from 81% to 97% by weight of betahistine is dissolved in 16 hours; and from 98% to 100% by weight of betahistine is dissolved in 24 hours. It also relates to the treatment of a vestibular disease or condition, more particularly in the treatment of Ménière's disease.